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1. Introduction
1.1. Development of the cardiovascular system
The development of the cardiovascular system is an early embryological event. From fertili‐
zation, it takes eight weeks for the human heart to develop into its definitive fetal structure.
During this period the system develops so it can 1) supply nutrients and oxygen to the
fetus, and 2) immediately start functionining after birth.
1.2. Early development of the circulatory system
1.2.1. Blood islands
During the third week of gestation angioblastic blood islands of mesoderm (angiogenic
clusters) appear in the yolk sac, chorion and body stalk. The innermost cells of these blood
islands are hematopoietic cells that give rise to the blood cell lines. The outermost cells give
rise to the endothelial cell layer of blood vessels. A series of blood islands eventually coalesce
to form blood vessels (fig 1).
1.2.2. Heart tube
By the middle of the third week of gestation angioblastic blood islands from the splanchnic
mesoderm appear and form a plexus of vessels lying deep into the horseshoe-shaped pro‐
spective pericardial cavity (fig 2). These small vessels develop into paired endocardial heart
tubes. The splanchnic mesoderm proliferates and develops into the myocardial mantle, which
gives rise to the myocardium. The epicardium develops from cells that migrate over the
myocardial mantle from areas adjacent to the developing heart (fig 3,4).
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Figure 2. Horseshoe-shaped prospective pericardial cavity
Figure 1. Angioblastic blood islands of mesoderm
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Figure 3. Endocardial heart tubes
Figure 4. Splanchnic mesoderm
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The bilateral endocardial heart tubes continue to develop and connect with a pair of vessels,
the dorsal aortae, located on either side of the midline. As the embryo develops, the lateral
folding and cephalic growth of the embryo shift the endocardial heart tubes medially, ventrally
and caudally. They fuse in the midline as a single endocardial heart tube. The endocardial
heart tube is surrounded by the myocardial mantle and between these two layers is the cardiac
jelly. The resulting heart tube is kept suspended in the pericardial cavity through the dorsal
mesocardium. When the single heart tube is formed, the embryo is in the fourth week of
gestation, is about 3 mm in length, has 4 - 12 somites, and the neural tube is beginning to form.
The heart now begins to beat (fig 5).
Figure 5. Endocardial heart tube
1.2.3. Vascular circuits
As the heart begins to beat, three sets of blood islands coalesce to form three vascular circuits.
Within the embryo an embryonic circuit forms (fig 6.)It consists of paired dorsal aortae that
arise from the endocardial heart tube and break up into capillary networds that supply blood
to the developing embryonic tissues. Blood is drained from these tissues byanterior and
posterior cardinal veins that drain into common cardinal veins, which in turn drain into the
endocardial heart tube.
Two extraembryonic circuits also form. The first is the vitelline (omphalomesenteric, yolk sac)
circuit. In this circuit blood from the dorsal aortae drain into vitelline arteries that in turn
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supply the yolk sac. The blood drains back to the heart tube via paired vitelline veins. The
second circuit is the umbilical (allantoic, placental) extraembryonic circuit. In this instance, the
dorsal aortae supply blood to umbilical arteries that in turn bring this now unoxygenated blood
back to the placenta. Blood from the placenta is carried to the heart tube via umbilical veins.
1.3. Formation of the primitive four chambered heart
As the endocardial heart tubes fuse, several bulges and sulci appear. From the cephalic end,
the bulges are the bulbus cordis (truncus arteriosus and the conus arteriosus), the primitive
ventricle, the primitive atrium and the sinus venosus (fig 7.) The veins connect to the heart
tube via the sinus venosus, while the paired dorsal aortae arise from aortic arches that in turn
arise from the aortic sac. The aortic sac is at the most cephalic end of the bulbus cordis. The
sulci are present as the bulboventricular sulcus, between the bulbus cordis and the ventricle,
and the atrioventricular sulcus, between the atrium and the ventricle.
Then, a rapid growth of the heart tube takes place, and the heart begins to convolute. With this
convolution the dorsal mesocardium begins to degenerate. During the process of convolution,
the first flexure seen is between the bulbus cordis and the ventricle. The bulbo-ventricular loop
that is formed shifts this region of the heart to the right and ventrally. The second flexure, the
atrioventricular loop, is between the atrium and the ventricle and this region of the heart is
shifted to the left and dorsally. As growth continues the atria shift cephalically.
Figure 6. Embryonic circuit forms
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The sinus venosus gradually shifts to the right to empty into the right atrium. The bulbo-
ventricular sulcus is represented inside the heart as the bulbo-ventricular flange. The bulbo-
ventricular flange and the muscular interventricular septum begin to separate the primitive
ventricle (which will become the left ventricle) from the proximal bulbus cordis (which will
become the definitive right ventricle). The atria continue to grow, and bulge forward on either
side of the bulbus cordis, and shift the bulbus medially. With increased blood flow the bulbo-
ventricular flange regresses. Thus, the primitive four-chambered heart is formed and blood
flows from the veins to sinus venosus, to atria, to ventricles, to conus, to truncus, to aortic sac,
to dorsal aorta.
Now the enlarging liver encroaches upon the developing vitelline and umbilical veins and
gradually all the blood will drain to the proximal right vitelline vein. The distal vitelline veins
will give rise to the portal system. The left umbilical vein remains and drains into the ductus
venosus, a shunt which allows blood to bypass the developing liver.
1.4. Septation of the heart
During the second month, the heart begins to septate into two atria, two ventricles, the
ascending aorta and the pulmonary trunk.
1.4.1. Atrial septation
Endocardial cushions develop in the dorsal (inferior) and ventral (superior) walls of the heart.
These grow toward each other as the cardiac jelly mesenchyme proliferates deep to the
endocardium. These cushions fuse and divide the common AV canal into the left and right AV
canals.
At the same time there is a developing septum from the dorsocranial atrial wall that grows
toward the cushions. This is the septum primum, and the intervening space is called the
 
Figure 7. Convolution of the Heart Tube
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foramen primum. As the septum reaches the endocardial cushions closing foramen primum,
a second opening, foramen secundum appears in septum primum. As foramen secundum
enlarges, a second septum, septum secundum forms to the right of septum primum. Septum
secundum forms an incomplete partition (lying to the right of foramen secundum) which
leaves an opening, the foramen ovale. The remaining portions of septum primum become the
valve of foramen ovale (fig 8).
Concurrently, the sinus venosus has shifted to the right as the proximal portions of the left
vitelline and umbilical veins are obliterated by the liver. The right sinus venosus becomes
incorporated into the right atrium forming the smooth portion of the right atrium. The
primitive right atrium is seen in the adult as the rough portion (auricle) of the right atrium.
The remainder of the left sinus horn is the coronary sinus and the oblique vein (of Marshall)
in the adult heart (fig 9).
On the left side, the primitive atrium is enlarged by the incorporation of tissue from the
original, single pulmonary vein and its proximal branches. This incorporated tissue is the adult
smooth left atrial wall through which four pulmonary veins empty independently. The
trabeculated left atrial appendage originated from the primitive left atrium.
 
Figure 8. Atrial Septation
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1.4.2. Ventricular septation
The muscular interventricular septum grows as a ridge of tissue from the caudal heart wall
toward the fused endocardial cushions. The remaining opening is the interventricular (IV)
foramen. The IV foramen is closed by the conal ridges, outgrowth of the inferior endocar‐
dial cushion, the right tubercle, and connective tissue from the muscular interventricular
septum. This portion of the I.V. septum is called the membranous part of the interventric‐
ular septum (fig 10).
 
Figure 10. Ventricular Septation
Figure 9. Atrial Development
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1.4.3. Septation of the bulbus cordis
Truncal swellings (ridges) appear first as bulges in the truncus on the right superior and the
left inferior walls. They enlarge and fuse in the midline to form the truncal (aorticopulmonary)
septum. This septum spirals as it develops distally, separating the distal pulmonary artery
from the aorta. At the same time, right dorsal and left ventral conal ridges form and fuse in
the midline. The conal septum helps dividing the proximal aorta from the pulmonary artery
and contributes to the membranous IV septum. The truncal and conal septa fuse to form a
180o spiral and together definitively form the aorta and the pulmonary artery. Cells that
contribute to the conal and the truncal septa are in part derived from neural crest cells that
migrate into these regions (fig 11).
 
Figure 11. Septation of the Bulbus Cordis
1.4.4. Cardiac valve fromation
Semilunar valves develop in the aorta and pulmonary artery as localized swellings of endo‐
cardial tissue. The atrioventricular valves develop as subendocardial and endocardial tissues
and project into the AV canal. These bulges are excavated from the ventricular side and
invaded by muscle. Eventually, all the muscle, except that remaining as papillary muscle,
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disappear and three cusps of the right AV (tricuspid) valve, and two cusps of the left AV
(mitral) valve remain as fibrous structures.
1.4.5. Development of the major arteries
The six pairs of aortic arches, develop in a cephalocaudal direction and interconnect the ventral
aortic roots and the dorsal aorta. They are never all present in the developing human heart.
Of the six pairs of aortic arches, most of the first, second and fifth arches disappear (fig 12).
Figure 12. Development of the Major Arteries
1.4.6. Development of the veins
The veins develop from the three major vascular circuits. As with the arteries they develop in
a cephalocaudal direction and as a consequence the precursors to the veins are never all present
at the same time. In addition, as new structures develop the course of veins changes.
In considering the development of the veins, the veins to the head are derived from the anterior
cardinal veins. New channels also develop such as the thymicothyroid anastomoses and the
external jugular veins and give rise to veins of the head and neck (fig 13).
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 Figure 13. Development of the Veins
In the trunk, one set of veins develops from the posterior cardinal veins and veins that develop
from it later in development, such as the subcardinal, supracardinal, and sacrocardinal veins.
These veins will give rise to the inferior vena cava, the renal, adrenal and gonadal veins, as
well as the azygos and hemiazygos viens (fig 14).
Figure 14. Development of Azygos Veins
The superior mesenteric vein (and perhaps the splenic vien) as well as the veins to the liver
develop from the vitelline (omphlomesenteric) veins. The ductus venosus develops as a new
structure that connects the left umbilical vein with the inferior vena cava (fig 12).
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2. The cardiomyopathies
Cardiomyopathy  is  a  chronic  disease  of  the  heart  muscle  (myocardium),  in  which  the
muscle  is  abnormally enlarged,  thickened,  and/or  stiffened.  The weakened heart  muscle
loses the ability to pump blood effectively, resulting in irregular heartbeats (arrhythmias)
and possibly even heart failure. Cardiomyopathy, a disease of the heart muscle, primari‐
ly  affects  the  left  ventricle,  which  is  the  main  pumping  chamber  of  the  heart.  Usually,
cardiomyopathy begins in the heart's lower chambers (the ventricles), but in severe cases
can  affect  the  upper  chambers,  or  atria.The  disease  is  often  associated  with  inadequate
heart  pumping and other heart  function abnormalities.  Cardiomyopathy is  not  common
but it can be severely disabling or fatal. Most people are only mildly affected by cardiomy‐
opathy and can lead relatively normal lives.However, people who have severe heart failure
may  need  a  heart  transplant.Cardiomyopathy  is  a  heart  condition  that  not  only  affects
middle-aged and elderly  persons,  but  can  also  affect  infants,  children,  and adolescents.
Cardiomyopathy  is  classified  as  either  "ischemic"  or  "nonischemic".  All  cases  related  to
children  and  teenagers  are  considered  "nonischemic"  cardiomyopathy.  Non-ischemic
cardiomyopathy  predominately  involves  the  heart's  abnormal  structure  and  function.  It
does not involve the hardening of arteries on the heart surface typically associated with
ischemic cardiomyopathy. Nonischemic cardiomyopathy can then be broken down into: 1)
"primary cardiomyopathy" where the heart is predominately affected and the cause may
be due to infectious agents or genetic disorders and 2) "secondary cardiomyopathy" where
the heart is affected due to complications from another disease affecting the body (i.e. HIV,
cancer, muscular dystrophy or cystic fibrosis).Cardiomyopathy is nondiscriminatory in that
it can affect any adult or child at any stage of their life. It is not gender, geographic, race
or  age  specific.  It  is  a  particularly  rare  disease  when  diagnosed  in  infants  and  young
children.  Cardiomyopathy  continues  to  be  the  leading  reason  for  heart  transplants  in
children.Pediatric cardiomyopathy is a rare heart condition that affects infants and children.
Specifically,  cardiomyopathy  means  disease  of  the  heart  muscle  (myocardium).  Several
different types of cardiomyopathy exist and the specific symptoms vary from case to case.
In some cases, no symptoms may be present (asymptomatic); in many cases, cardiomyop‐
athy is a progressive condition that may result in an impaired ability of the heart to pump
blood; fatigue; heart block; irregular heartbeats (tachycardia); and, potentially, heart failure
and  sudden  cardiac  death.There  are  numerous  causes  for  a  complex  disease  such  as
cardiomyopathy.  For  the  majority  of  diagnosed  children,  the  exact  cause  remains  un‐
known (termed "idiopathic").  In some cases,  it  may be related to an inherited condition
such  as  a  family  history  of  cardiomyopathy  or  a  genetic  disorder  such  as  fatty  acid
oxidation,  Barth  syndrome,  orNoonan syndrome.  Cardiomyopathy  can  also  be  a  conse‐
quence of another disease or toxin where other organs are affected. Possible causes include
viral infections (Coxsackie B - CVB), auto-immune diseases during pregnancy, the build-
up  of  proteins  in  the  heart  muscle  (amyloidosis),  and  an  excess  of  iron  in  the  heart
(hemochromatosis).  Excessive  use  of  alcohol,  contact  with  certain  toxins,  complications
from AIDS, and the use of some therapeutic drugs (i.e.  doxorubicin) to treat cancer can
also contribute to the development of the disease.
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3. Pediatric cardiomyopathies
Pediatric cardiomyopathy is a rare heart condition that affects infants and children.There is a
vast amount of literature on adult cardiomyopathy but not all of the information is relevant
to children diagnosed with the disease. Unfortunately, there has been little research and focus
on pediatric cardiomyopathy over the years. Consequently, the causes are not well understood.
Pediatric cardiomyopathy is more likely to be due to genetic factors while lifestyle or envi‐
ronmental factors play a greater role in adult cardiomyopathy.
In rare cases, pediatric cardiomyopathy may be a symptom of a larger genetic disorder that
may not be immediately detected. For example, when an infant or young child is diagnosed
with dilated cardiomyopathy, a rare genetic heart disease called Barth Syndrome or a mito‐
chondrial defect (i.e. Kearns-Sayre syndrome) may be the cause. Similarly, a child with severe
hypertrophic cardiomyopathy may actually have Noonan Syndrome, Pompe disease (type II
glycogen storage disease), a fatty acid oxidation disorder, or mitochondrial HCM. It is therefore
important for any diagnosed child to be properly evaluated for other suspected genetic
disorders. A thorough evaluation remains a complicated and expensive process due to the
large number of rare genetic causes, the broad range of symptoms and the existence of many
specialized biochemical, enzymatic and genetic tests. Verifying a diagnosis may require getting
additional blood, urine or tissue tests and consulting other specialists such as a neurologist
and geneticist.
Cardiomyopathy in children may also present differently from diagnosed teenagers or adult.
It is considered unusual when an infant or a child is diagnosed with symptoms at such a young
age. Typically, symptoms are not apparent until the late teens or adult years when most
patients are diagnosed. With hypertrophic cardiomyopathy, the disease commonly develops
in association with growth and is detected when a child progresses through puberty. Even in
genetically affected family members, a child that carries the muted gene from birth may appear
to have a normal heart and be asymptomatic until puberty.
A diagnosis at a young age usually, but not always, signifies a serious heart condition that
requires aggressive treatment. The concern lies in the uncertainty of how the heart muscle will
respond with each additional growth spurt. With some older children, the condition may
stabilize over time with the aid of certain medications or surgery. In severe cases, small children
may experience progressive symptoms quickly leading to heart failure. This presentation
contrasts with most diagnosed adults who may only have minor symptoms without serious
limitations or major problems for years.Aside from differences in the cause and manifestation,
cardiomyopathy may also progress differently in children than adults. When children are
diagnosed at an early age, the prognosis may be poor depending on the form of cardiomyop‐
athy and the stage of the disease. For example, dilated cardiomyopathy can progress quite
rapidly when diagnosed in young children. Up to 40% of diagnosed children with dilated
cardiomyopathy fail medical management within the first year of diagnosis and of those that
survive many have permanently impaired heart function. Children diagnosed with hypertro‐
phic cardiomyopathy seem to fare better but the outcome is highly variable.Mortality and heart
transplant rates of childhood cardiomyopathies are much higher than in adults due to the
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rarity and uncertainty of the disease. Less than optimal outcomes may be attributed to the
more fragile state of infants and young children or it may be a function of the disease's
advanced progression associated with another genetic disorder. Another unfortunate reason
is that cardiomyopathy is not usually detected until the end stage when obvious symptoms of
heart failure are apparent. Cardiomyopathy can be easily missed in routine check-ups when
there are no obvious symptoms (i.e heart murmur) or when there is no reason for diagnostic
testing (i.e. no family history of the disease).
3.1. What causes cardiomyopathy?
Although pediatric cardiomyopathy is one of the leading causes of cardiac death in children,
an explanation for why it occurs remains unknown. Most cases are familial conditions that are
genetically transmitted, but the disease can also be acquired during childhood. The most
common cause for acquired cardiomyopathy is myocarditis, a viral infection that weakens the
heart muscle. Other causes for acquired cardiomyopathy include: 1) cardiovascular conditions
(i.e. Kawasaki disease, congenital heart defect, hypertension, cardiac transplantation or
surgery), 2) infectious or inflammatory diseases, 3) immunologic diseases (i.e. HIV), 4) obesity
or dietary deficiencies, 5) toxin reactions (i.e. drug, alcohol, radiation exposure), 6) connective
tissue and autoimmune diseases, 7) endocrine diseases and 8) pregnancy related complica‐
tions. Persistent rhythm problems or problems of the coronary arteries, either congenital or
acquired, can also lead to a weakening of the heart.
It is being increasingly recognized that certain genetic mutations are the primary cause for
pediatric cardiomyopathy. Mutations are defects in the DNA spiral, the protein structure of
many genes. The abnormalities in DNA involve a displacement in the sequence of one or more
of the amino acids that make up a gene protein. The disease is either inherited through one
parent who is a carrier (autosomal dominant transmission with a 50% chance of recurrence)
or through both parents who each contribute a defective gene (autosomal recessive transmis‐
sion with a 25% chance of recurrence). Cardiomyopathy can also be inherited by maternal
transmission (X-linked). Research continues to focus on identifying the specific genes that
cause cardiomyopathy and better understanding how these genetic abnormalities contribute
to the disease. However, it is a complex process with multiple diverse genes producing
extremely variable outcomes. Many children with hypertrophic cardiomyopathy (50-60%) and
to a lesser degree with dilated cardiomyopathy (20-30%) have a family history of the disease.
Recent advancements in genetic research show that hypertrophic cardiomyopathy involves
defects in the sarcomere genes and can be inherited in an autosomal dominant manner. Dilated
cardiomyopathy involves defects in the cytoskeleton genes and can be inherited autosomal
dominant, autosomal recessive or X-linked. In some cases, cardiomyopathy can be related to
another inherited metabolic or congenital muscle disorder such as Noonan syndrome, Pompe
disease, fatty acid oxidation defect or Barth syndrome. Most often, symptoms of these
disorders present early in life.Although there is a long list of possible causes for cardiomyop‐
athy, few of them are directly treatable and most therapy is aimed at treating the secondary
effects on the heart.
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According to the Pediatric Cardiomyopathy Registry, cardiomyopathies can be grouped into
five categories based on the specific genetic cause of the disease:
• myocarditis and other viral infections (27%),
• familial inherited cardiomyopathies (24%),
• neuromuscular disorders associated with cardiomyopathy (22%),
• metabolic disorders (16%),
• malformation syndromes associated with cardiomyopathy (10%).
3.2. Myocarditis and other viral infections
This a leading cause in children with cardiomyopathy and is more commonly associated with
DCM. It is caused by viral infections that cause the body's immune system to malfunction
damaging/inflaming the heart muscle tissue while attacking the invading virus. At this point,
it is unknown whether certain children have a certain genetic makeup that may make them
more susceptible to contracting myocarditis.
3.3. Familial inherited cardiomyopathies
Isolated familial cardiomyopathy is considered when the child does not show features of
metabolic or muscular disorders, and there is a known family history of cardiomyopathy. In
affected families with HCM, ARVD, DCM, and RM, the condition is predominately inherited
in an autosomal dominant manner where an affected parent has a 50% chance of passing the
defective gene to his/her offspring. In rare cases, ARVC, DCM and HCM can be inherited
through autosomal recessive or maternal transmission where unaffected parent(s) have a 25%
chance of an affected child with each pregnancy.
Although the genetic defect is the same in all members of an individual family, there are
variable outcomes and severity of the disease in different family members. The disease's
manifestation can range from minimal abnormality and no symptoms to severe complications
within the same family. In some families it may appear that the mutated gene skips a generation
but in reality the defective gene may not have expressed itself fully in a particular family
member, and therefore echocardiograms may appear normal.
3.3.1. Neuromuscular disorders associated with cardiomyopathy
Neuromuscular diseases associated with cardiomyopathy include those that affect the nerve
or skeletal muscles. These include muscular dystrophies (i.e. Duchenne and Becker), congen‐
ital myopathies, metabolic myopathies, and ataxias (i.e. Friedreich Ataxia). Common symp‐
toms are decreased muscle tone, weakness beginning after infancy, loss of motor control,
decreased muscle relaxation and decreased muscle bulk. Almost all of the neuromuscular
diseases associated with cardiomyopathy have a genetic basis.
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3.3.2. Metabolic disorders
Inborn errors of metabolism consist of numerous infiltrative storage diseases, abnormal energy
production, biochemical deficiencies and disorders related to toxic substances accumulating
in the heart. This category also includes mitochondrial abnormalities (i.e. MELAS, MERRF,
respiratory chain diseases, mitochondrial myopathies), fatty acid oxidation defects (carnitine
deficiency, VCHAD, LCHAD, LCAD, MCAD), Pompe disease and Barth syndrome. When the
demand for energy exceeds what the body can supply (i.e. during illness, physical stress or
decreased oral intake), patients with impaired energy metabolism are unable to maintain their
body's biochemical stability. This may lead to low blood sugar, excessive acidity in the blood
and/or high ammonia levels that put additional strain on the heart.Metabolic disorders are
inherited by autosomal recessive transmission (each parent contributes a defective gene) or X-
linked transmission (mother contributes defective gene). Usually patients appear to be
physically normal in early childhood but as the body's energy production continues to be
impaired, toxic substances may accumulate throughout the body leading to multiple organ
failure. Common symptoms include muscle weakness, decreased muscle tone, growth
retardation, developmental delays, failure to thrive, constant vomiting and lethargy. In critical
states, the child may exhibit stroke like symptoms, seizures, have low blood sugar, and be
unable to use the body's fuel correctly.
In contrast, patients with storage diseases such as Pompe, Cori, and Andersen disease cannot
break down glycogen, the storage form of sugar. These syndromes are characterized by
problems with growth, brain dysfunction, decreased muscle tone, muscle weakness, and
symptoms of heart failure.
3.3.3. Malformation syndromes associated with cardiomyopathy
Malformation syndromes are characterized by minor and major physical abnormalities with
distinctive facial features. It is caused by genetic mutations through autosomal dominant,
autosomal recessive, or X-linked recessive inheritance. It can also be cause by a chromosomal
defect where a specific chromosome is deleted or duplicated. Noonan syndrome is the most
common form associated with pediatric cardiomyopathy. Common symptoms include short
stature, webbed neck, wide set eyes, low set ears and extra skin folds.
3.4. Forms of cardiomyopathy
There are four main types of nonischemic cardiomyopathy that are recognized by the World
Health Organization: dilated (DCM), hypertrophic (HCM), restrictive (RCM) and arrhythmo‐
genic right ventricular (ARVC). Each form is determined by the nature of muscle damage.
With some patients, cardiomyopathy may be classified as more than one type or may change
from one type to another over time. According to the pediatric cardiomyopathy survey, dilated
cardiomyopathy is the most common (58%), followed by hypertrophic cardiomyopathy (30%)
and a few cases of restrictive cardiomyopathy (5%) and arrhythmogenic right ventricular
cardiomyopathy (5%). Although not formally categorized by the World Health Organization,
left ventricular non-compaction cardiomyopathy (LVNC) is increasingly being recognized.
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With each type of cardiomyopathy, symptoms and reactions to pharmaceutical or surgical
therapies may vary widely among patients.
4. Dilated cardiomyopathy
Dilated or congestive cardiomyopathy (DCM) is diagnosed when the heart is enlarged
(dilated) and the pumping chambers contract poorly (usually left side worse than right). A
diagram and echocardiogram comparing a normal heart and a heart with DCM (fig. 15)
Figure 15. A normal heart is shown on the left compared to a heart with dilated cardiomyopathy on the right.
This condition is the most common form of cardiomyopathy and accounts for approximately
55–60% of all childhood cardiomyopathies. It can have both genetic and infectious/environ‐
mental causes.It is more commonly diagnosed in younger children with the average age at
diagnosis being 2 years. Dilated cardiomyopathy can be familial (genetic), and it is estimated
that 20–30% of children with DCM have a relative with the disease, although they may not
have been diagnosed or have symptoms.
4.1. Signs and symptoms of DCM
Dilated cardiomyopathy can appear along a spectrum of no symptoms, subtle symptoms or,
in the more severe cases, congestive heart failure (CHF), which occurs when the heart is unable
to pump blood well enough to meet the body tissue needs for oxygen and nutrients.When only
subtle symptoms exist, infants and young children are sometimes diagnosed with a viral upper
respiratory tract infection or recurrent “pneumonia” without realizing that a heart problem is
the basis for these symptoms. Older children and adolescents are less likely to be diagnosed
with viral syndromes and more likely to present with decreased exercise capacity or easy
fatigability. With CHF, babies and young children will usually have more noticeable clinical
changes such as irritability, failure to thrive (poor gain weight), increased sweating especially
with activities, pale color, faster breathing and/or wheezing. In older children, congestive heart
failure can manifest as difficulty breathing and/or coughing, pale color, decreased urine output
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and swelling, excessive sweating, and fatigue with minimal activities. Until the diagnosis is
made in many children, chronic coughing and wheezing, particularly during activities, can be
misinterpreted as asthma.Some patients with DCM caused by viral myocarditis (weakened,
enlarged heart muscle usually due to a viral infection) can have a rapid increase in the number
and severity of CHF symptoms such that within 24–48 hours the child can become very ill
requiring emergency hospitalization, and occasionally, advanced life support.Symptoms due
to heart rhythm problems (or arrhythmias, which means irregular, fast or slow heart rates) can
also be either the first symptom or a symptom that appears after other symptoms have led to
a diagnosis of DCM. Symptoms of rhythm problems include palpitations (feeling of funny or
fast heart beats), syncope (fainting), seizures (convulsions), or even sudden cardiac arrest
(heart stops beating effectively requiring resuscitation). These symptoms can occur at any age
and with any stage of cardiomyopathy, even if other more severe symptoms of congestive
heart failure have not yet appeared.
4.2. Diagnosis of DCM
Once there is clinical suspicion based on the patient history and physical exam, the diagnosis
of DCM is primarily based on echocardiography. With this test, will be using ultrasound beams
to evaluate the heart looking for dilated chambers and decreased pump function. Along with
the echocardiogram, there are other tests that will likely be done to confirm the diagnosis or
provide clues as to the cause.A chest X-ray will show the heart size and can be used as a
reference to follow increases in heart size that may occur over time. An electrocardiogram, or
EKG, records the electrical conduction through the heart and is used to look for evidence of
thickened or enlarged chambers as well as abnormal heart beats that can occur in children with
this diagnosis. To more completely evaluate for the presence or absence of these abnormal
heart rhythms, which may effect treatment, your doctor may also order a Holter monitor which
records heart beats over a 24–48 hour period. A treadmill test can also be useful in some
children (beyond age 5–7 years) who can cooperate with this study. This exercise test is used
to assess the energy reserve child’s heart and, in cases when children do not respond ade‐
quately to medicines, this test may also help predict the need for heart transplantation.De‐
pending on child’s age, a battery of blood tests may be done in order to identify treatable causes
for the cardiomyopathy. This may include testing for certain viral infections such as adenovirus
and the Coxsackie viruses as they have been associated with DCM especially in younger
children. In many cases, no cause is discovered, and the cardiomyopathy may be referred to
as “idiopathic” (cause unknown). Many heart failure specialists believe this “idiopathic” form
of the cardiomyopathy is genetic. While genetic screening has not yet become a standard
procedure, some physicians may send blood to molecular testing labs located in a few centers
around the country so that limited genetic testing can be performed looking for possible
mutations currently known to cause dilated cardiomyopathy. evaluation, usually with echo,
of other family members is recommended to rule out presence of this disease in other close
relatives (parents, siblings).
Finally, in more advanced cases of DCM, cardiac catheterization may be performed. During
this procedure, a catheter (thin plastic tube) will be slowly advanced through an artery or vein
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into the heart (while watching its course on a TV monitor) so that pressures within the heart
chambers can be measured. A cardiac biopsy, which involves removing tiny pieces of heart
muscle for inspection under the microscope, may be performed to help distinguish between
infectious and genetic causes.
4.3. Current treatment
Currently, there are no therapies that can “cure” DCM; however, many treatments are
available that can improve symptoms and decrease risk in children with DCM. The choice of
a specific therapy depends on the clinical condition of the child, the risk of dangerous events
and the ability of the child to tolerate the therapy. In the following sections, current medical
and non-medical therapies for DCM are summarized.
4.4. Medical therapy
The majority of children with DCM have signs and symptoms of heart failure. The most
common types of medications used to treat heart failure include diuretics, inotropic agents,
afterload reducing agents and beta-blockers.
Diuretics, sometimes called “water pills,” reduce excess fluid in the lungs or other organs by
increasing urine production. The loss of excess fluid reduces the workload of the heart, reduces
swelling and helps children breathe more easily. Diuretics can be given either orally or
intravenously. Common diuretics include furosemide, spironolactone, bumetanide and
metolazone. Common side effects of diuretics include dehydration and abnormalities in the
blood chemistries (particularly potassium loss).
Inotropic Agents are used to help the heart contract more effectively. Inotropic medications
and are most commonly used intravenously to support children who have severe heart failure
and are not stable enough to be home. Common types of inotropic medications include:
• Digoxin (taken by mouth): improves the contraction of the heart. Side effects include low
heart rate, and, with high blood levels, vomiting and abnormal heart rhythm.
• Dobutamine, dopamine, epinephrine, norepinephrine (intravenous medications given in
the hospital): medications that increase blood pressure and the strength of heart contrac‐
tions. Side effects include increased heart rate, arrhythmias and for some, constriction of the
arteries.
• Vasopressin (intravenous medication): increases blood pressure and improves blood flow
to the kidneys. Side effects include excessive constriction of the arteries and low sodium.
• Milrinone (intravenous medication): improves heart contraction and decreases the work of
the heart by relaxing the arteries. Side effects include low blood pressure, arrhythmias and
headaches.
Afterload Reducing Agents reduce the work of the heart by relaxing the arteries and allowing
the blood to flow more easily to the body. Common afterload reducing medications include:
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• Angiotensin converting enzyme inhibitors (ACE inhibitors): captopril, enalapril, lisinopril,
monopril (taken by mouth). Side effects include low blood pressure, low white blood cell
count, high potassium levels and kidney or liver abnormalities.
• Angiotensin I Blocker: Losartan (taken by mouth). Side effects include diarrhea, muscle
cramps and dizziness.
• Milrinone is an inotropic agent (see above) that also relaxes the arteries.
Beta-blockers  slow  the  heartbeat  and  reduce  the  work  needed  for  contraction  of  the
heart  muscle.  Slowing  down  the  heart  rate  can  help  to  keep  a  weakened  heart  from
overworking.  In  some  cases,  beta-blockers  allow  an  enlarged  heart  to  become  more
normal  in  size.  Common beta-blockers  (taken by mouth)  include carvedilol,  metoprolol,
propanolol  and  atenolol.  Side  effects  include  dizziness,  low  heart  rate,  low  blood
pressure,  and,  in  some cases,  fluid  retention,  fatigue,  impaired school  performance  and
depression.In  addition to  improving the  symptoms of  heart  failure,  ACE inhibitors  and
beta-blockers  have  been  shown  to  return  the  heart  size  toward  normal  and  lessen  the
number  of  deaths  and  hospitalizations  in  adult  patients  with  dilated  cardiomyopathy
without symptoms.  An ACE inhibitor is  recommended in children with dilated cardiomy‐
opathy  even  in  the  absence  of  symptoms.  Currently,  no  firm  recommendations  are
available  for  beta-blockers  in children.
4.5. Anticoagulation medications
In children with a heart that does not contract well, there is a risk of blood clots forming inside
the heart possibly leading to a stroke. Anticoagulation medications, also known as blood
thinners are often used in these situations. The choice of anticoagulation drug depends on how
likely it is that a blood clot will form. Less strong anticoagulation medications include aspirin
and dipyridamole. Stronger anticoagulation drugs are warfarin, heparin, and enoxaparin;
these drugs require careful monitoring with regular blood testing. While variable, common
side effects of anti-coagulants include excessive bruising or bleeding from otherwise minor
skin injuries, interaction with other medications and, for warfarin, fluctuations in anticoagu‐
lation blood levels caused by changes in daily dietary intake.
4.6. Anti-arrhythmia medications
In some DCM patients,  especially those with very dilated and poorly contractile  ventri‐
cles,  there may be a higher risk of an abnormal, life-threatening heart rhythm (ventricu‐
lar  tachycardia),  and  medications  are  used  to  prevent  or  control  this  abnormal  rhythm
which  then  keeps  the  heart  beating  in  a  regular  pattern.  Common  anti-arrhythmia
medications  include:  amiodarone,  procainamide and lidocaine.  General  side  effects  may
include  slower  heart  rate,  lower  blood  pressure,  GI  upset  (nausea/constipation),  head‐
ache,  depressed mood, difficulties concentrating,  dizziness,  and skin rash among others.
Consult  your cardiologist  for  drug-specific  side effects  once a  particular  anti-arrhythmic
medicine has been prescribed.
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4.7. Pacing therapies for DCM
4.7.1. Pacemakers
Pacemakers are small, battery-operated devices that are placed under the skin of the chest or
abdomen and attached to electrical wires (leads) which are threaded to the heart. Depending
on which type of pacemaker is used, these leads are attached to muscle tissue either on the
inside or outside of the heart. The devices monitor the heartbeat and help maintain a regular
rhythm in children who are prone to have abnormal heartbeats.In some patients with DCM,
the heart rate can become too slow either due to abnormally slow conduction of impulses
through the heart or as a side effect of medications. In those instances, a “back-up” pacemaker
can be implanted to help maintain an appropriate heart rate.Conversely, as mentioned above,
patients with DCM can develop abnormally fast, life-threatening arrhythmias (ventricular
tachycardia and/or fibrillation). Implantable cardioverter defibrillators (ICDs) can be used in
those children to convert these arrhythmias to a normal rhythm.Finally, a bi-ventricular pacing
system has recently become part of the standard therapy in adults with end-stage heart failure
associated with DCM, and this treatment modality is currently being evaluated in children.
4.7.2. Implantable Cardioverter Defibrillator (ICD)
ICDs are designed to prevent sudden death from a serious arrhythmia known as ventricular
tachycardia or fibrillation. An ICD constantly monitors heart rate, and when ventricular
tachycardia or fibrillation is detected, the ICD delivers a shock to the heart that restores normal
rhythm. ICDs are used in patients with hypertrophic cardiomyopathy who are felt to be at
high risk for a sudden death and in children with dilated cardiomyopathy who have serious
ventricular arrhythmias.
4.7.3. Biventricular pacemaker
In recent promising studies in adult patients with dilated cardiomyopathy, a special pace‐
maker that can pace both the right and left ventricles has been designed. This system, which
has to be specially timed, allows the two ventricles to contract together and improves the
synchrony of contraction between the walls of the left ventricle. Study results have shown that,
when added to other medical treatments, this mode of pacing has helped some patients live
longer with fewer hospitalizations and, in some cases, has decreased the need for transplan‐
tation. At the time of this publication, use of bi-ventricular pacing in children is in the early
stages of development. It is not yet known which children may benefit most from this form of
pacing or the best way to implant the system
4.8. Surgical options for DCM
No surgery has been effective in improving the heart function in dilated cardiomyopathy. In
a few patients with a severely dilated left ventricle and a very leaky (regurgitant) mitral valve,
surgery to repair or replace the mitral valve may help the heart function improve temporarily.
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Heart transplantation is the only effective surgery offered for patients with DCM who have
severe heart failure that does not respond to medications or other treatments.
4.9. Cardiac assist devices (Mechanical hearts)
Cardiac assist devices are machines that do the work of the heart using a mechanical pump to
deliver blood to the body. Cardiac assist devices are implanted when all other therapies have
failed and the heart failure is severe. They improve blood flow to the body and allow other
organs to recover from the stress of heart failure. These devices are typically used as bridges
to transplantation. That is, they are used to support a child either until the heart function has
recovered enough to effectively circulate blood through the body or until a suitable donor
organ can be found. In pediatric patients, they are designed as a temporary means of support
and cannot be used as a permanent alternative to the child’s own heart or a transplanted heart.
Potential complications of cardiac assist devices include infection, blood clots, stroke and
mechanical problems with the devices themselves. There are a variety of cardiac assist devices
available. The type of cardiac assist device that is used for an individual child depends on body
size and also the type of assist support needed.
4.10. Heart transplantation
Dilated cardiomyopathy is one of the leading reasons for heart transplantation in children.
Heart transplant is only considered in children who have such serious heart disease that there
are no other medications or support devices available to sustain the child. A heart transplant
offers the child with DCM the chance to return to a normal lifestyle.
While a donor heart can cure the symptoms of heart failure and greatly improve survival, it is
a major operation with considerable risks and long-term complications. Once a transplant is
done, other concerns arise, such as infection, organ rejection, coronary artery disease, and the
side effects of medications.
5. Hypertrophic cardiomyopathy
Most often diagnosed during infancy or adolescence, hypertrophic cardiomyopathy (HCM) is
the second most common form of heart muscle disease, is usually genetically transmitted, and
comprises about 35–40% of cardiomyopathies in children. A diagram and echocardiogram
comparing a normal heart and a heart with HCM (fig.16).
“Hypertrophic” refers to an abnormal growth of muscle fibers in the heart. In HCM, the thick
heart muscle is stiff, making it difficult for the heart to relax and for blood to fill the heart
chambers. While the heart squeezes normally, the limited filling prevents the heart from
pumping enough blood, especially during exercise.Although HCM can involve both lower
chambers, it usually affects the main pumping chamber (left ventricle) with thickening of the
septum (wall separating the pumping chambers), posterior wall or both. With hypertrophic
obstructive cardiomyopathy (HOCM), the muscle thickening restricts the flow of blood out of
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the heart. Often, leakage of the mitral valve causes the blood in the lower chamber (left
ventricle) to leak back into the upper chamber (left atrium). In less than 10% of patients, the
disease may progress to a point where the heart muscle thins and the left ventricle dilates
resulting in reduced heart function similar to that seen in DCM.HCM is most often diagnosed
during infancy or adolescence. Gene defects can be familial, and it is estimated that 50–60% of
children with HCM have a relative with the disease, although they may not have been
diagnosed or have symptoms.
5.1. Signs and symptoms of HCM
There is tremendous variation in how HCM presents and progresses. While some children
have no or mild symptoms, others may have more severe symptoms including heart failure.
Some patients develop abnormal heart rhythms (arrhythmias) that may put them at increased
risk for sudden cardiac death. Children under 1 year of age often have symptoms of congestive
heart failure whereas older children may be symptom free and, therefore, may be unaware
that HCM is present. Onset of symptoms often coincides with the rapid growth and develop‐
ment of late childhood and early adolescence. The strenuous exercise of competitive sports
has also been known to make symptoms of HCM more apparent. Disease severity and
symptoms are related to the extent and location of the hypertrophy and whether there is
obstruction to blood leaving the heart or valve leakage from the left-sided pumping chamber
Figure 16. A normal heart is shown on the left compared to a heart with a hypertrophic cardiomyopathy on the right.
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back into the left atrium above. The first sign of HCM may be a murmur, although this is
usually absent in the non-obstructive form of HCM. Symptoms in children with HCM can
include dyspnea (shortness of breath during exercise), angina (chest pain), presyncope (light-
headedness or dizziness), syncope (fainting), exercise intolerance or palpitations/arrhythmias
(irregular heartbeats). Symptoms in infants may be more difficult to detect but include
difficulty breathing, poor growth, excessive sweating (diaphoresis) or crying and agitation
during feeding thought to be due to chest pain Children with severe HCM may have symptoms
of heart failure such as difficulty breathing, swelling around the eyes and legs (edema),
tiredness or weakness, coughing, abdominal pain and vomiting. Mild symptoms of heart
failure can also resemble asthma. Children with HCM may also develop an abnormal heartbeat
(arrhythmia), either beating too fast (tachycardia) or too slow (bradycardia). Symptoms
resulting from rhythm problems can appear without a child having congestive heart failure
or other more obvious symptoms of HCM. The risk of sudden death from arrhythmia is higher
with this form of cardiomyopathy compared with other forms of pediatric myopathy espe‐
cially among adolescent patients. Finally, in some cases of HCM (especially those with extreme
wall thickness), the disease evolves towards progressive wall thinning and LV chamber
dilation until theheart appears to have all the features of DCM. In these cases, a family history
of HCM, a prior echocardiogram that showed HCM or a cardiac biopsy may help differentiate
between the two.
5.2. Diagnosis of HCM
Once suspected, the diagnosis of hypertrophic cardiomyopathy is established with an
echocardiogram (or ultrasound of the heart) looking for abnormally thick walls predominantly
in the left pumping chamber (left ventricle). In addition, the extent of obstruction or muscular
narrowing through the outlet of the left ventricle to the aorta (main vessel which carries blood
to the body) will be assessed. This diagnosis can only be made after other potential causes of
abnormal wall thickening (i.e., aortic valve stenosis, coarctation of the aorta, high blood
pressure, etc.) are eliminated either by physical exam or echocardiogram. An electrocardio‐
gram, or EKG, which records the electrical impulses sent through the heart, may show evidence
of thickened pumping chambers. Many cardiologists will order a Holter monitor to record you
child’s heartbeats over a 24–48 hour period. This will allow your physician to check for
abnormal, and sometimes life-threatening, heart rhythms, which can occur more often in
children with HCM. To further estimate child’s risk for developing these abnormal heart
rhythms, some cardiologists may ask, in children old enough to cooperate, to perform an
exercise treadmill test.Since the cause of this form of cardiomyopathy varies and depends on
child’s age, additional laboratory testing may be requested. In some cases, an accumulation of
abnormal proteins or sugars (glycogen) may occur in the heart causing the increased wall
thicknesses. In others, genetic mutations or abnormalities in the mitochondria (powerhouses
of the cells) produce this effect. Genetic testing is available for some but not all forms of HCM.
In the next decade, as more genetic bases for HCM are identified, genetic testing may become
a routine part of the HCM evaluation.
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5.3. Current treatment for HCM
Currently, there are no therapies that can “cure” HCM; however, many treatments are
available that can improve symptoms and potentially decrease risk in children with HCM. The
choice of a specific therapy depends on the clinical condition of the child, the risk of dangerous
events and the ability of the child to tolerate the therapy. In the following sections, treatments
for HCM are summarized.
5.4. Medical therapies
Medications are used to treat children with HCM who have symptoms such as difficulty
breathing, chest pain, decreased activity tolerance or fatigue and generally include beta-
blocking and calcium channel-blocking medicines. Beta-blocking medications are used to slow
the heartbeat and allow the heart to fill more completely when the thick muscle in the
ventricular septum narrows the outflow of blood from the heart. These medications can cause
excessive slowing of the heart rate, low blood pressure, dizziness, and in some cases, fluid
retention, fatigue, impaired school performance and depression. Calcium channel blockers
improve the filling of the heart by reducing the stiffness of the heart muscle, and are used in
patients with chest pain or breathlessness. Side effects can include excessive slowing of the
heart rate and lower blood pressure. Common calcium channel blockers are verapamil and
diltiazem. Diuretics, which must be used with caution in this disease, are used to decrease
fluid accumulation (when present) from the lungs in children with severe hypertrophic
cardiomyopathy. In the case of HCM which has progressed into a myopathy with DCM
features (occurs relatively infrequently as a later stage of HCM - see previous discussion of
HCM), therapies used to treat HCM will no longer be effective, and standard medicines for
the treatment of DCM will be substituted.
5.5. Pacing therapies for HCM
5.5.1. Implantable Cardioverter Defibrillator (ICD)
ICDs are designed to prevent sudden death from a serious arrhythmia known as ventricular
tachycardia or fibrillation. An ICD constantly monitors heart rate, and when ventricular
tachycardia or fibrillation is detected, the ICD delivers a shock to the heart that restores normal
rhythm. ICDs are used in patients with hypertrophic cardiomyopathy who are felt to be at
high risk for a sudden death or have documented serious ventricular arrhythmias.
5.6. Surgery for HCM
Septal myomectomy is a surgery that is performed in patients with hypertrophic cardiomy‐
opathy when symptoms of heart failure have developed because the thickened muscle of the
septum (the wall dividing the two sides of the heart) has narrowed (obstructed) the blood flow
out of the heart, and medical therapy has not been effective. The surgery involves removing
the muscle that has obstructed the blood flow. While septal myomectomy is effective in
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controlling symptoms, it does not stop hypertrophy from progressing, nor does it treat the life-
threatening abnormal rhythms associated with HCM.
5.7. Heart transplantation
Currently, transplantation for HCM is not routinely performed. Two exceptions include
medically refractory ventricular arrhythmias, and HCM which has developed features of DCM
not responsive to standard DCM therapy. A heart transplant will offer that child the chance
to return to a normal lifestyle. While a donor heart can cure the symptoms of heart failure and
greatly improve survival, it is a major operation with considerable risks and long-term
complications. Once a transplant is done, other concerns arise, such as infection, organ
rejection, coronary artery disease, and the side effects of medications.
6. Restrictive cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare form of heart muscle disease that is characterized
by restrictive filling of the ventricles. In this disease the contractile function (squeeze) of the
heart and wall thicknesses are usually normal, but the relaxation or filling phase of the heart
is very abnormal. This occurs because the heart muscle is stiff and poorly compliant and does
not allow the ventricular chambers to fill with blood normally. This inability to relax and fill
with blood results in a “back up” of blood into the atria (top chambers of the heart), lungs and
body causing the symptoms and signs of heart failure(fig.17).
Figure 17. Restrictive Cardiomyopathy (RCM)
Cardiomyopathies306
Within the broad category of cardiomyopathy, RCM is the least common in children, account‐
ing for 2.5–5% of the diagnosed cardiomyopathies The average age at diagnosis is 5 to 6 years.
RCM appears to affect girls somewhat more often than boys. There is a family history of
cardiomyopathy in approximately 30% of cases. In most cases the cause of the disease is
unknown (idiopathic), although a genetic cause is suspected in most cases of pediatric RCM.
6.1. Signs and symptoms of RCM
In children the first symptoms of RCM often seem related to problems other than the heart.
The most common symptoms at first may appear to be lung related. Children with RCM
frequently have a history of “repeated lung infections” or “asthma.” In these cases, referral to
a cardiologist eventually occurs when a large heart is seen on chest x-ray. The second most
common reason for referral is an abnormal physical finding during a doctor’s examination.
Children who have ascites (fluid in the abdomen), hepatomegaly (enlarged liver) and edema
(fluid causing puffy looking feet, legs, hands or face) are often sent to see a gastroenterologist
first. Referral to a cardiologist is made when additional cardiac signs or symptoms occur, a
chest x-ray is found to be abnormal or no specific gastrointestinal cause is found for the edema
or enlarged liver. When the first sign of the disease is an abnormal heart sound, or signs of
heart failure are recognized, then earlier referral to a cardiologist occurs. In approximately 10%
of cases, fainting is the first symptom causing concern. Unfortunately, sudden death has been
the initial presentation in some patients.
6.2. Diagnosis of RCM
Restrictive cardiomyopathy is among the rarest of childhood cardiomyopathies. Its diagnosis
is difficult to establish early in the clinical course due to the lack of symptoms. Therefore, in
many cases, this diagnosis is made only after presentation with symptoms such as decreased
exercise tolerance, new heart sound (gallop), syncope (passing out) or chest pain with
exercise.Once suspected, there are certain tests that can help confirm this diagnosis. An
electrocardiogram, or EKG, which records the electrical conduction through the heart, can be
very helpful. This can show abnormally large electrical forces from enlargement of the atria
(upper chambers) of the heart. An echocardiogram, or ultrasound of the heart, can provide
additional clues to help make this diagnosis. Generally, in children with RCM, the echocar‐
diogram shows marked enlargement of the atria (upper chambers), normal sized ventricles
(lower chambers) and normal heart function. In more advanced disease states, pulmonary
artery pressure (blood pressure in the lungs) will be increased and can often be estimated
during the echocardiogram.Cardiac catheterization is usually the next procedure done to
confirm the diagnosis. During this procedure, a catheter (thinplastic tube) will be slowly
advanced through an artery or vein into the heart (while watching its course on a TV monitor)
so that pressures within the heart chambers can be measured. These measurements often show
significantly elevated pressures during the relaxation period of the heart (when it fills with
blood before the next beat) and varying degrees of increased pulmonary artery pressure (which
can confirm the echo estimates) in the absence of any other structural heart disease. In very
rare cases, based on clinical symptoms and prior laboratory evaluation, a cardiac biopsy may
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be performed. This involves removing tiny pieces of heart muscle for inspection under the
microscope to search for potential causes of this condition (such as amyloidosis or sarcoidosis,
which are common causes of RCM in adults but rarely in pediatric patients). Finally, since
childhood RCM is often genetic and in many cases will be inherited, once this diagnosis is
established, your doctor will likely request that parents, siblings of the patient and sometimes
other close relatives be screened with an echocardiogram to rule out the presence of this disease
in other family members.
6.3. Current treatment
Currently, there are no therapies that can “cure” RCM; however, some treatments are available
that can improve symptoms in children with RCM. The choice of a specific therapy depends
on the clinical condition of the child, the risk of dangerous events and the ability of the child
to tolerate the therapy.
6.4. Medical therapies to treat RCM and associated heart failure
Some children with RCM have signs and symptoms of heart failure due to the abnormal
relaxation properties of the heart muscle. The most common types of medications used to treat
heart failure under these circumstances include diuretics, beta-blockers and occasionally
afterload reducing agents.
Diuretics, sometimes called “water pills,” reduce excess fluid in the lungs or other organs by
increasing urine production. Diuretics can be given either orally or intravenously. Common
diuretics include furosemide, spironolactone, bumetanide and metolazone. Common side
effects of diuretics include dehydration and abnormalities in the blood chemistries (particu‐
larly potassium loss). In patients with RCM, diuretics must be used very carefully and given
only in doses to treat extra lung and abdominal fluid without inducing excessive fluid loss as
this may cause symptomatically low blood pressure.
Beta-blockers slow the heartbeat and increase the relaxation time of the heart. This may allow
the heart to fill better with blood before each heart beat and decrease some of the symptoms
created by the stiff pumping chambers. Common beta-blockers (taken by mouth) include
carvedilol, metoprolol, propanolol and atenolol. Side effects include dizziness, low heart rate,
low blood pressure, and, in some cases, fluid retention, fatigue, impaired school performance
and depression.
6.5. Anticoagulation medications
In children with a  heart  that  does not  relax well,  there is  a  risk of  blood clots  forming
inside the heart possibly leading to a stroke. Anticoagulation medications, also known as
blood  thinners,  are  often  used  in  these  situations.  The  choice  of  anticoagulation  drug
depends  on  how  likely  it  is  that  a  blood  clot  will  form.  Less  strong  anticoagulation
medications include aspirin and dipyridamole. Stronger anticoagulation drugs are warfar‐
in,  heparin,  and enoxaparin;  these  drugs  require  careful  monitoring  with  regular  blood
testing. While variable,  common side effects of anticoagulants include excessive bruising
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or bleeding from otherwise minor skin injuries, interaction with other medications and, for
warfarin, fluctuations in anticoagulation blood levels caused by changes in daily dietary
intake.  Information regarding which food groups can significantly  affect  warfarin levels
can be obtained from your cardiologist.
6.6. Surgery for restrictive cardiomyopathy
No surgery has been effective in improving the heart function in restrictive cardiomyopathy.
Heart transplantation is the only effective surgery offered for patients with RCM, particularly
those who already have symptoms at the time of diagnosis or in whom reactive pulmonary
hypertension exists.
6.7. Heart transplantation
Since there are no proven effective therapies for children with RCM, transplantation is the only
known intervention for this disease. This is especially true in cases where evaluation has
demonstrated the presence of pulmonary hypertension, which can be fatal if not treated. For
children with RCM, heart transplantation can address both the abnormal heart function as well
as associated pulmonary hypertension. A heart transplant offers the child with RCM the
chance to return to a normal lifestyle. While a donor heart can cure the symptoms of heart
failure and greatly improve survival, it is a major operation with considerable risks and long-
term complications. Once a transplant is done, other concerns arise, such as infection, organ
rejection, coronary artery disease, and the side effects of medications.
7. Miscellaneous (Rare) cardiomyopathies
There are other forms of cardiomyopathy which comprise only a very small percentage of the
total (~2–3%) number of cardiomyopathies in children. These cardiomyopathies may have
overlapping features with any of the previous types described and include arrhythmogenic
right ventricular dysplasia (ARVD), mitochondrial and left ventricular non-compaction
cardiomyopathies (LVNC).Patients with ARVD have dilated, poorly functioning right
ventricles which have fatty deposits within the walls and are at risk for abnormally fast, life-
threatening heart rhythms (ventricular tachycardia). This myopathy can be diagnosed (usually
due to the abnormal rhythms) either in early infancy or later in adolescence/adulthood by
echocardiogram or MRI, and its prognosis depends, in part, on the age at presentation.Mito‐
chondrial myopathies are rare and often present early in life. Hearts in the affected patients
are often thick-walled (hypertrophic), although dilated hearts with poor function can also
occur with this type of myopathy. This cardiomyopathy is caused by abnormalities in the
mitochondria of the cells, which are small structures within each cell responsible for generating
the energy the cell uses for its normal activities. These cardiomyopathies are often associated
with other muscle, liver, neurologic and/or developmental abnormalities and are usually
genetically passed from an affected mother to her children.Finally, left ventricular non-
compaction (LVNC) cardiomyopathy is characterized by deep trabeculations (or crevices)
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within muscle of the left ventricular walls. These hearts may have features of both dilated and/
or hypertrophic cardiomyopathy. Conditions associated with LVNC include mitochondrial
and metabolic disorders as well as systemic (whole body) processes such as Barth syndrome.
Barth syndrome has a constellation of abnormalities including cyclic neutropenia or periodic
fluctuations in the white blood cell count (which may not be apparent in early infancy),
hypotonia (weak muscles) and LVNC cardiomyopathy. Barth syndrome has recently been
linked to an abnormality in the X-chromosome and is passed from mother to son.
7.1. Symptoms of ARVD, mitochondrial and LVNC cardiomyopathies
Symptoms (the problems noted by the child and/or family) and signs (the problems detected
by your physician) of cardiomyopathy in children are dependent on several factors including
the type, cause and severity of the specific cardiomyopathy, the age when the problems started,
and the effects of treatment. Since patients with ARVD generally have symptoms consistent
with DCM, and patients with mitochondrial or LVNC cardiomyopathies can have symptoms
seen with either HCM or DCM, families are encouraged to review the relevant sections written
for dilated and hypertrophic cardiomyopathies within this brochure to become familiar with
the pertinent symptoms for each of these cardiomyopathy types.
7.2. Diagnosis of ARVD, mitochondrial and LVNC cardiomyopathies
As with presenting symptoms, the clinical diagnosis of these rare forms of cardiomyopathy
will depend on the features of the specific cardiomyopathy. That is, the diagnostic criteria in
a child with ARVD will generally follow that of DCM while the mitochondrial and LVNC
myopathies will follow that of either DCM or HCM depending on the clinical manifestations
of the myopathy. In addition to what is discussed in the diagnostic sections written for the
dilated and hypertrophic forms of cardiomyopathy found elsewhere in this brochure, the
following comments highlight a few details specific for the diagnosis of each of these rare
cardiomyopathies.
The diagnosis of ARVD can be difficult especially in children given its low incidence. However,
opposed to the usual form of DCM, which involves the left ventricle to a greater extent, ARVD
typically involves the right ventricle preferentially and often times, the clinical suspicion for
ARVD can be further explored with MRI (Magnetic Resonance Imaging) which, in many cases,
can differentiate fatty deposits from muscle tissue within the wall of the right ventricle that
are commonly seen with this disease. The diagnosis can usually be confirmed with visualiza‐
tion of significant fatty deposition within the right ventricular walls (where muscle should be)
from biopsy specimens obtained during cardiac catheterization.
Patients with mitochondrial cardiomyopathy often have other associated medical problems
such as hearing or vision problems, skeletal muscle weakness in the arm and leg muscles and/
or central nervous system issues including learning problems, developmental delay or loss of
developmental milestones. Once suspected, in addition to the cardiac assessment (for DCM or
HCM) outlined elsewhere in this brochure, a muscle biopsy performed to evaluate both
structure and function of the mitochondria can help verify this diagnosis. A cardiac biopsy is
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generally not useful because the volume of muscle tissue necessary to perform the mitochon‐
drial analyses can only be safely obtained from arm or leg muscles.
The diagnosis of LVNC can often by strongly suspected when deep crevices or trabeculations
are noted with the walls of the left ventricle during an echocardiogram. Very few other cardiac
diagnoses have these specific findings. Genetic testing may become more available in the near
future to assess identified causes of LVNC especially among male children and those suspected
of having Barth syndrome (see following discussion on the G4.5 mutation testing).
7.3. Current treatment
Currently, there are no therapies that can “cure” cardiomyopathy; however, many treatments
are available that can improve symptoms and decrease risk in children with cardiomyopathy.
The choice of a specific therapy depends on the type of cardiomyopathy, the clinical condition
of the child, the risk of dangerous events and the ability of the child to tolerate the therapy.
8. Living with cardiomyopathy
The diagnosis of cardiomyopathy affects many areas of a child’s life. The following sections
outline the general approaches to living with cardiomyopathy. It is important that specific
recommendations are developed by the team caring for the child with cardiomyopathy
9. Diet
All children with cardiomyopathy should follow a healthy diet. Certain types of cardiomy‐
opathy are associated with an inability to digest certain types of food, and in these cases, a
special diet is developed in consultation with metabolic specialists. In children with the dilated
subtype of cardiomyopathy and heart failure, a low salt diet is recommended to avoid fluid
retention. Some children with heart failure may not grow well. In these cases, a diet that
increases calories is recommended. Children who are taking some medications may have low
levels of magnesium or potassium and a diet that has a higher amount of one or both of these
two electrolytes may be recommended. Some children with severe heart failure can retain extra
body fluid, and it may be necessary to limit the amount that a child can drink to prevent fluid
from accumulating in the lungs.
10. Long term prognosis
The long-term outlook of pediatric cardiomyopathy continues to be unpredictable because it
occurs with such a wide spectrum of severity and outcome. Even if a child has a family history
of the disease, the degree to which he or she is affected can vary considerably from his/her
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parents or siblings. The overall prognosis for a child also depends on the type of cardiomy‐
opathy and the stage the disease is first diagnosed. Although there is no cure for the disease,
symptoms and complications can be managed and controlled with regular monitoring. Some
children will stabilize with treatment and lead a relatively normal lifewith fewphysical activity
restrictions. Other children with a more serious form of cardiomyopathy may face more
limitations, need specialized care and encounter minor developmental delays. Occasionally
children with certain types of cardiomyopathy do improve, but the majority do not show any
recovery in heart function. For the most severe cases, a heart transplant may be necessary.
Children diagnosed with DCM or RCM are more likely to require a transplant; it is less
common with HCM. Post transplant survival continues to improve with two year survival
rates at 80 percent and ten-year survival rates near 60 percent. Longer-term survival remains
to be determined but is expected to improve with more medical progress and research.
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